Nyxoah SA (NYXH) stock
NYXHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.86−0.04 (-4.10%)
Close on Nov 18, 2026Market cap $37.13MP/E –Yield –
Nyxoah EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Nyxoah's EPS for the twelve months ending Dec 31, 2022 was -1.21 EUR. For fiscal 2025 it was -2.36 EUR. The highest annual figure on record is -0.68 EUR in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2.36 EUR | – |
| FY2024 | Dec 31, 2024 | -1.81 EUR | – |
| FY2023 | Dec 31, 2023 | -1.54 EUR | – |
| FY2022 | Dec 31, 2022 | -1.21 EUR | – |
| FY2021 | Dec 31, 2021 | -1.16 EUR | – |
| FY2020 | Dec 31, 2020 | -0.68 EUR | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -0.58 EUR | – |
| Q2 FY2025 | Jun 30, 2025 | -0.55 EUR | – |
| Q2 FY2024 | Jun 30, 2024 | -0.43 EUR | – |
| Q2 FY2023 | Jun 30, 2023 | -0.45 EUR | – |
| Q4 FY2022 | Dec 31, 2022 | -0.51 EUR | – |
| Q3 FY2022 | Sep 30, 2022 | -0.24 EUR | – |
| Q2 FY2022 | Jun 30, 2022 | -0.19 EUR | – |
| Q4 FY2021 | Dec 31, 2021 | -0.24 EUR | – |
| Q3 FY2021 | Sep 30, 2021 | -0.35 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?